Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.35 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.35 |
| ▸ | CD69 | Q07108 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.31 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25445487 | 0.86 | MDK (0.36) | LGALS3LGALS8LGALS4CD69STAT3 | |
| SCHEMBL18079538 | 0.86 | MDK (0.36) | LGALS3LGALS8LGALS4CD69STAT3 | |
| SCHEMBL15274901 | 0.82 | LGALS3 (0.45) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL18589697 | 0.82 | LGALS3 (0.45) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL16659352 | 0.82 | LGALS3 (0.45) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL17212844 | 0.75 | LGALS3 (0.46) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL20175842 | 0.74 | LGALS3 (0.52) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL16247707 | 0.73 | LGALS3 (0.39) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL17718782 | 0.72 | LGALS3 (0.47) | LGALS3LGALS8LGALS4CD69ALDH1A1 | |
| SCHEMBL17849187 | 0.71 | LGALS3 (0.55) | LGALS3LGALS8LGALS4CD69ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150056254-A1 | METHOD FOR MANUFACTURING TRANSDERMALLY DELIVERED HYALURONIC ACID-PROTEIN CONJUGATE AND TRANSDERMALLY DELIVERED HYALURONIC ACID-PROTEIN CONJUGATE MANUFACTURED USING SAME | PHI BIOMED CO., LTD. (KR) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056254-A1 | METHOD FOR MANUFACTURING TRANSDERMALLY DELIVERED HYALURONIC ACID-PROTEIN CONJUGATE AND TRANSDERMALLY DELIVERED HYALURONIC ACID-PROTEIN CONJUGATE MANUFACTURED USING SAME | CD44, CUTA, HIRA | LGALS3 2497/4885LGALS8 2300/4885LGALS4 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.